CAI
Caris Life Sciences, Inc.27.60
+0.90+3.37%
Dec 16, 4:00:01 PM EST
Earnings Call Transcripts
This Quarter (Q4 '25)
No earnings call transcript available yet
Last Quarter (Q3 '25)
No earnings call transcript available
Key Stats
Market Cap
7.79BP/E (TTM)
-Basic EPS (TTM)
-3.52Dividend Yield
0%Recent Filings
8-K
Bylaws hike derivative suit threshold
Caris Life Sciences amended its bylaws on October 30, 2025, raising the threshold for shareholders to initiate derivative proceedings to 3% beneficial ownership of outstanding common stock. This change, approved by the board, aims to curb frivolous lawsuits while protecting broader investor interests. It tightens governance amid the company's emerging growth status. Such barriers may deter small activists, yet invite scrutiny from larger holders.
8-K
Q2 revenue surges 81%
Caris Life Sciences reported Q2 2025 revenue of $181.4 million, up 81.3% year-over-year, fueled by 85.9% growth in molecular profiling services and 22% higher clinical case volume. Gross margins expanded to 62.7%, while Adjusted EBITDA turned positive at $16.7 million, reflecting improved reimbursements and operational leverage post-IPO. Momentum builds. Full-year revenue guidance projects $675–$685 million, a 64–66% increase, though risks from reimbursement decisions linger.
10-Q
Q2 FY2025 results
Caris Life Sciences posted Q2 FY2025 revenue of $181.4M, up 81.3% y/y from $100.0M, driven by molecular profiling services surging 85.9% y/y to $162.9M on 22.0% higher clinical case volume and improved ASPs from MI Cancer Seek's FDA approval and launch. Gross margins expanded sharply to 62.7% from 37.6%, while operating loss narrowed to $18.0M from $67.0M y/y, though net loss widened to $71.8M from $66.2M due to $17.9M debt extinguishment and $17.9M fair value changes tied to the June IPO. Cash swelled to $720.4M post-IPO net proceeds of $519.5M, bolstering liquidity against $400.0M term debt at 10.8% (due 2028); free cash flow improved to $(28.1)M YTD from $(141.2)M. The IPO converted all preferred stock and notes, flipping shareholders' deficit to $452.9M equity. Yet regulatory scrutiny persists, with a DOJ probe into Medicare billing compliance risking fines or recoupments.
8-K
IPO closes with $494M proceeds
Caris Life Sciences completed its initial public offering on June 20, 2025, selling 23,529,412 shares of common stock at $21.00 per share for gross proceeds of $494.1 million before expenses. This milestone triggered the effectiveness of its amended Certificate of Formation and Bylaws, aligning governance with public company standards. IPO success bolsters funding for molecular diagnostics growth. Yet risks from market volatility linger.
IPO
Employees
Sector
Industry
BIAF
bioAffinity Technologies, Inc.
1.38-0.10
CAHO
Caro Holdings Inc.
0.55+0.00
CARM
Carisma Therapeutics, Inc.
0.05+0.00
CBIO
Crescent Biopharma, Inc.
12.92-0.29
CDIO
Cardio Diagnostics Holdings Inc
3.10+0.02
CDXS
Codexis, Inc.
1.68+0.05
CRBU
Caribou Biosciences, Inc.
1.69-0.02
HWAIF
HealWELL AI Inc.
0.64+0.00
MAIA
MAIA Biotechnology, Inc.
1.23-0.12
MRVI
Maravai LifeSciences Holdings,
3.59-0.08